Concepts (112)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 10 | 2025 | 1188 | 1.140 |
Why?
|
| Sinus Thrombosis, Intracranial | 2 | 2024 | 48 | 1.100 |
Why?
|
| Neoplasms | 4 | 2025 | 3024 | 0.800 |
Why?
|
| Tracheostomy | 1 | 2024 | 201 | 0.760 |
Why?
|
| Hematologic Neoplasms | 1 | 2025 | 294 | 0.730 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2025 | 888 | 0.710 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2024 | 809 | 0.550 |
Why?
|
| Anemia, Sickle Cell | 3 | 2024 | 341 | 0.460 |
Why?
|
| Child, Preschool | 13 | 2025 | 14788 | 0.400 |
Why?
|
| Infant | 12 | 2025 | 13158 | 0.400 |
Why?
|
| Warts | 2 | 2022 | 17 | 0.380 |
Why?
|
| Thrombotic Microangiopathies | 2 | 2023 | 53 | 0.380 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 2087 | 0.380 |
Why?
|
| Child | 18 | 2025 | 25733 | 0.350 |
Why?
|
| Retrospective Studies | 14 | 2025 | 17378 | 0.350 |
Why?
|
| Neutropenia | 2 | 2022 | 201 | 0.340 |
Why?
|
| Adolescent | 13 | 2025 | 20505 | 0.340 |
Why?
|
| Lung Diseases | 2 | 2024 | 401 | 0.330 |
Why?
|
| Graft vs Host Disease | 3 | 2024 | 622 | 0.310 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2024 | 639 | 0.270 |
Why?
|
| Follow-Up Studies | 3 | 2025 | 5455 | 0.260 |
Why?
|
| Hemorrhage | 3 | 2025 | 508 | 0.260 |
Why?
|
| Prognosis | 3 | 2025 | 5074 | 0.260 |
Why?
|
| Pericardial Effusion | 1 | 2025 | 71 | 0.230 |
Why?
|
| Interleukin-15 | 1 | 2025 | 96 | 0.220 |
Why?
|
| beta-Thalassemia | 1 | 2023 | 29 | 0.210 |
Why?
|
| Tranexamic Acid | 1 | 2023 | 24 | 0.210 |
Why?
|
| Antifibrinolytic Agents | 1 | 2023 | 40 | 0.210 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 46 | 0.200 |
Why?
|
| Anticoagulants | 2 | 2024 | 599 | 0.200 |
Why?
|
| Postpartum Hemorrhage | 1 | 2023 | 101 | 0.200 |
Why?
|
| Lymphopenia | 1 | 2022 | 39 | 0.190 |
Why?
|
| Agammaglobulinemia | 1 | 2022 | 43 | 0.190 |
Why?
|
| Respiration, Artificial | 1 | 2024 | 500 | 0.180 |
Why?
|
| Humans | 23 | 2025 | 133390 | 0.180 |
Why?
|
| Male | 11 | 2025 | 65685 | 0.180 |
Why?
|
| Anemia, Diamond-Blackfan | 1 | 2020 | 10 | 0.170 |
Why?
|
| Female | 11 | 2025 | 71455 | 0.170 |
Why?
|
| Ribosomal Proteins | 1 | 2020 | 73 | 0.170 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2022 | 214 | 0.170 |
Why?
|
| Cohort Studies | 3 | 2024 | 5175 | 0.170 |
Why?
|
| Incidence | 2 | 2025 | 3396 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 551 | 0.160 |
Why?
|
| Neuroblastoma | 1 | 2025 | 540 | 0.160 |
Why?
|
| Hodgkin Disease | 1 | 2022 | 298 | 0.160 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 368 | 0.140 |
Why?
|
| Transplantation Conditioning | 3 | 2023 | 300 | 0.130 |
Why?
|
| Intensive Care Units, Pediatric | 3 | 2025 | 485 | 0.120 |
Why?
|
| Stroke | 1 | 2023 | 1068 | 0.110 |
Why?
|
| Alemtuzumab | 2 | 2023 | 88 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2024 | 3155 | 0.100 |
Why?
|
| Receptors, CXCR4 | 2 | 2022 | 71 | 0.090 |
Why?
|
| Developing Countries | 1 | 2012 | 288 | 0.080 |
Why?
|
| Activated Protein C Resistance | 1 | 2009 | 2 | 0.080 |
Why?
|
| Young Adult | 4 | 2025 | 9852 | 0.080 |
Why?
|
| Renal Veins | 1 | 2009 | 34 | 0.080 |
Why?
|
| Factor V | 1 | 2009 | 17 | 0.080 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2009 | 71 | 0.080 |
Why?
|
| Thrombophilia | 1 | 2009 | 40 | 0.080 |
Why?
|
| Lipoprotein(a) | 1 | 2009 | 137 | 0.070 |
Why?
|
| Venous Thrombosis | 1 | 2009 | 168 | 0.070 |
Why?
|
| Infant, Newborn | 4 | 2025 | 8586 | 0.070 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2025 | 66 | 0.060 |
Why?
|
| Texas | 2 | 2025 | 3688 | 0.060 |
Why?
|
| Israel | 1 | 2024 | 48 | 0.060 |
Why?
|
| Epilepsy | 1 | 2012 | 892 | 0.060 |
Why?
|
| Transfusion Reaction | 1 | 2024 | 40 | 0.060 |
Why?
|
| United States | 3 | 2025 | 11677 | 0.060 |
Why?
|
| Gangliosides | 1 | 2025 | 73 | 0.060 |
Why?
|
| Europe | 1 | 2025 | 380 | 0.050 |
Why?
|
| Hemolysis | 1 | 2024 | 113 | 0.050 |
Why?
|
| Natural Killer T-Cells | 1 | 2025 | 84 | 0.050 |
Why?
|
| Busulfan | 1 | 2023 | 45 | 0.050 |
Why?
|
| Risk Factors | 3 | 2025 | 11085 | 0.050 |
Why?
|
| Carmustine | 1 | 2022 | 25 | 0.050 |
Why?
|
| Melphalan | 1 | 2022 | 45 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2023 | 692 | 0.050 |
Why?
|
| Cytarabine | 1 | 2022 | 100 | 0.050 |
Why?
|
| Respiratory Insufficiency | 1 | 2024 | 239 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 285 | 0.050 |
Why?
|
| Unrelated Donors | 1 | 2021 | 70 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 417 | 0.040 |
Why?
|
| Rituximab | 1 | 2022 | 164 | 0.040 |
Why?
|
| Biopsy | 1 | 2024 | 1300 | 0.040 |
Why?
|
| Penetrance | 1 | 2020 | 111 | 0.040 |
Why?
|
| Consensus | 1 | 2023 | 737 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 1 | 2020 | 781 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 429 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2023 | 1088 | 0.040 |
Why?
|
| Pedigree | 1 | 2020 | 1694 | 0.030 |
Why?
|
| Lung | 1 | 2024 | 1557 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2020 | 2781 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 2237 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1313 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1349 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 648 | 0.030 |
Why?
|
| Biomarkers | 1 | 2023 | 3424 | 0.030 |
Why?
|
| Aged | 2 | 2022 | 21605 | 0.030 |
Why?
|
| Lebanon | 1 | 2012 | 7 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2023 | 6570 | 0.020 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2012 | 91 | 0.020 |
Why?
|
| Heart Failure | 1 | 2024 | 2420 | 0.020 |
Why?
|
| Hematuria | 1 | 2009 | 55 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2024 | 12971 | 0.020 |
Why?
|
| Point Mutation | 1 | 2009 | 360 | 0.020 |
Why?
|
| Heparin | 1 | 2009 | 224 | 0.020 |
Why?
|
| Homozygote | 1 | 2009 | 560 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2009 | 930 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2009 | 997 | 0.010 |
Why?
|
| Genotype | 1 | 2009 | 2804 | 0.010 |
Why?
|
| Middle Aged | 1 | 2022 | 29208 | 0.010 |
Why?
|
| Adult | 1 | 2022 | 31786 | 0.010 |
Why?
|